The New American by Angeline Tan
SINGAPORE — Before Covid-19, Singapore did not have a single facility manufacturing finished vaccines. Nonetheless, over the past two years, five pharmaceutical companies have decided to establish plants projected to produce over a billion doses yearly in the city-state of around six million inhabitants.
The vaccines range from traditional types like live-attenuated and recombinant vaccines to those with mRNA technology, with the first slated to be unveiled as early as 2023.
Observers have credited the sudden influx of investments to experiences garnered during Covid-19. Pharmaceutical firms have seized on Covid-19 to expand worldwide while seeking more flexibility to churn out vaccines for future pandemics…
We need your help to keep Caravan to Midnight going,
please consider donating to help keep independent media independent.
